Predicted to enable glycosaminoglycan binding activity. Predicted to be involved in extracellular matrix organization; positive regulation of cell-substrate adhesion; and spinal cord development. Predicted to be located in extracellular matrix. Predicted to be active in interstitial matrix. Orthologous to human VIT (vitrin); INTERACTS WITH bisphenol A; cadmium dichloride; Cuprizon.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VIT mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of VIT mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VIT mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VIT mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of VIT mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VIT mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of VIT mRNA
[potassium bromate co-treated with bisphenol A] affects the expression of VIT mRNA and [XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [potassium bromate affects the expression of VIT mRNA]